Abstract 1768
Background
Taste changes can frequently be observed in oncological patients undergoing chemotherapy and are reported as being among the most distressing side effects, along with fatigue, nausea, vomiting, and hair loss. The prevalence of taste changes have been reported in the range of 46%–77%. The aim of this descriptive study was to evaluate taste changes experienced by cancer patients who receive chemotherapy and associated factors with taste changes.
Methods
This is a descriptive a study. The sample of the study consisted of 154 patients who received chemotherapy at Gayrettepe Florence Nightingale Hospital during the period of February 2018 to July 2018. Data were collected by using the patient İnformation form and Chemotherapy-induced Taste Alteration Scale (CiTAS). Mann-Whitney U test, Kruskal-Wallis test, and Spearman Correlation analysis were used to evaluate the data.
Results
The mean age of patients was 57,40±12,748 years, 62.3% of them were women, 43.5% of them were university graduates, 73.4% were married and 70.8% of them were employed in any job. According to CiTAS scores, the most discomfort in taste patients experienced was because of nausea, vomiting, odor disturbance and loss of appetite during the chemotherapy process. According to CiTAS score the least discomfort experienced by patients were tasting basic flavors including the taste of the sweet, salty, bitter flavors and the broth. As a result of the comparison of CiTAS score some sociodemographic and medical characteristics of patients, it was found that women experience more paraguzi and fantoguzi than men. As the age of the patients increased, the problems in taste were decreased. Patients who do not take other drugs than chemotherapy have fewer taste problems.
Conclusions
In conclusion, it is recommended to include changes in taste sensation along with other side effects in the evaluation of treatment-related processes of cancer patients, and to add practices related to management of taste changes in the care plan of the patients by taking into account the factors that may be associated with taste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract